1. Fecal microbiota transplantation showed noninferiority to vancomycin therapy in treating primary Clostridioides difficile infection.
2. The FMT group had higher clinical cure rates and lower disease recurrence compared to the vancomycin group.
3. The trial highlighted potential advantages of FMT over first-line antibiotic therapy, including reduced antibiotic use and minimal invasiveness.
4. Safety profile and mortality outcomes were similar between the FMT and vancomycin groups, with no treatment-related adverse events.
5. The study emphasizes the importance of a healthy gut microbiome and supports the paradigm shift toward microbiome restoration as first-line therapy for Clostridioides difficile infection.

Source: Annals of Internal Medicine and Editorial